Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NB202
- Development stage
- Unknown
- Lead developer
- NeoLogics Bioscience
- Modality
- Antibody-Based Therapeutics
01
Overview
NB202: sourced facts only. name: "NB202 has demonstrated high affinity binding to human TIM3 and PD-1 in the low nanomolar range." [DOI:10.1158/1538-7445.am2024-2733]; target: "NB202 has demonstrated high affinity binding to human TIM3 and PD-1 in the low nanomolar range." [DOI:10.1158/1538-7445.am2024-2733]; developer: "1NeoLogics Bioscience Co. Ltd., Suzhou, China." [DOI:10.1158/1538-7445.am2024-2733]; modality: "NB202 is a bispecific anti-PD1/TIM-3 antibody that has been designed to optimize the therapeutic response of anti-PD1 therapy" [DOI:10.1158/1538-7445.am2024-2733]; stage: "Moreover, in an anti-PD1 resistant mouse model, NB202 has shown promising efficacy results." [DOI:10.1158/1538-7445.am2024-2733]
02
Targets
Beyond the preview
Go deeper on NB202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NB202.